Drug news
NICE rejects Forxiga (BMS/AstraZeneca) as a treatment for Type 2 Diabetes
In a draft guidance published 1 February 2013, The National Institute of Health and Clinical Excellence (NICE) is minded not to recommend Forxiga (dapagliflozin) from BMS and Astra Zeneca, in combination therapy for treating Type 2 Diabetes. NICE is requesting further clarification and information from the manufacturers ahead of the second Appraisal Committee meeting in March 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.